Intravitreal injections: what are they and how are they given?

Written in association with: Dr Gabriella De Salvo
Published:
Edited by: Aoife Maguire

How are intravitreal injections used in ophthalmology?

Intravitreal injections are used to treat retinal vascular conditions such as neovascular age-related macular degeneration (AMD), diabetic maculopathy, and macular oedema (fluid) associated with a retinal vein occlusion. They are injected into the back of the eye in order to stop/limit leakage from retinal blood vessels and develop due to increased vascular endothelial growth factor VEGF and/or intraocular inflammation.

What type of drugs are injected this way?

Anti-VEGF (vascular endothelial growth factor), or steroid implant can be injected into the eye. Approved anti-VEGF drugs include Lucentis, Eylea, Vabysmo and biosimilars. Steroid implants used by ophthalmologists are Ozurdex and Iluvien.

 

How are intravitreal injections given, and how many are usually needed?

Before undergoing the intravitreal procedure, patients will receive anaesthetic drops and/or an anaesthetic injection on the surface of the eye. They will also be given an antiseptic solution which will be used in order to clean the surface of the eye and the periocular skin (the skin of the eyelid or around the eye).

 

Following this, a speculum will be applied to the eyelids to keep the eye open during the procedure. The injection is given into the external quadrant of the eye while the patient is looking down or up. After the procedure, they may feel some pressure and see black floaters.

 

Are there any side effects or potential risks involved?

Like any medical procedure, intravitreal injections pose some risks. Small superficial haemorrhages and floaters are very common following the procedure. Other complications such as raised intraocular pressure, cataracts and retinal tear/detachment may occur, however, these are very rare. A severe intraocular infection called endophthalmitis may also occur, but again, is extremely rare, with an incidence of 1:1000.

 

How safe and effective are intravitreal injections?

Intravitreal injections are the standard of care for many retinal vascular conditions. The benefit of having the treatment outweighs the small risk of having complications. They are safe and effective in controlling many retinal vascular conditions and aim to improve or stabilise vision.

 

Initially, Anti-VEGFs are given monthly but the interval is slowly increased once the condition has reached stability in terms of vision and repeated macular scans called OCT (optical coherence tomography). Intervals between injections will be guided by the OCT appearance. Steroid implants are long lasting and are not indicated to treat neovascular AMD.

 

 

If you require intravitreal injections and would like to speak to Dr De Salvo, you can book an appointment through her Top Doctors profile today.

By Dr Gabriella De Salvo
Ophthalmology

Dr Gabriella De Salvo is an internationally recognised consultant ophthalmologist who is based in Southampton and has over 20 years of experience. She provides highly professional and personalised care to adults and paediatric patients aged 3 and older.

Her areas of expertise include the diagnosis and treatment of medical retina conditions such as age-related macular degeneration (AMD)retinal vein occlusion, diabetic retinopathy and central serous chorioretinopathy. Furthermore, she regularly performs procedures such as intravitreal injections of anti-VEGF and intravitreal steroid implants. In fact, she has performed over 10,000 intravitreal injections of VEGF and steroid implants for retinal conditions. As an expert in diagnosing and treating challenging cases, she is available to provide a second opinion for rare and complex retinal disorders as well as for other conditions. 

Based on the work she has published, she ranks in the top 2% of medical retinal specialists in the world.

Dr De Salvo graduated as Medical Doctor at the University of Messina in Italy and completed her specialist training in Ophthalmology at the University of Palermo, Italy. During her training she won various scholarships and was able to deepen her studies at the Wills Eye Hospital in Philadelphia in the USA and at the University hospital in Vienna, Austria. She completed over a year of advanced training in Medical Retina at Moorfields Eye Hospital, London. She is a keen researcher and lecturer and regularly publishes her work in international peer-reviewed journals and is the principal investigator in various clinical trials. She is actively involved in the teaching of ophthalmologists, allied health professionals and medical students.

Dr De Salvo also works in collaboration with prestigious pharmaceutical companies in the development and research of new medicaments. Specifically she works with Novartis, Bayer, Roche, AbbVie, Boehringer Ingelheim, Teva, Heidelberg Engineering. She sits on national and international advisory boards for the development of innovative molecules to treat eye diseases. She is also Clinical Outcome Lead for Ophthalmology at University Hospital Southampton. She is a fellow of the Royal College of Ophthalmologist and is also a certified trainer and appraiser for the Royal College of Ophthalmologists. She has won various prizes during her career and a few clinical excellence awards.

In addition to ophthalmology, she has a special interest in facial and anti-wrinkle assessment.

View Profile

Overall assessment of their patients


  • Related procedures
  • Microdermoabrasion
    Microneedling
    Dark circles
    Mesotherapy
    Facelift
    Neck lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Peeling
    Facial paralysis
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.